1Contos M J, Sanyal Aj. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease [J]. Adv Anat Pathol,2002,9( 1 ) :37-51.
2McCullough, Arthur J. Update on nonalcoholic fatty liver disease [J]. J Clin Gastroenterol,2002,34(3 ) :255.
3Haffner SM, Gonzalez C, Miettinen H, et al. A prospective analysis of the HOMA model. The Mexico city diabetes study [ J ]. Diabetes Care,1996,19(10) :1 138-1 141.
4Contos M J, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease [ J]. Adv Anat Pathol,2002,9( 1 ) :37-51.
5McCullough, Arthur J. Update on nonalcoholic fatty liver disease[ J]. J Clin Gastroenterol,2002,34(3 ) :255.
7Kelley DE, McKolanis TM, Hegazi RA, et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab, 2003, 285: E906-E916.
8Meigs JB, Wilson PW, Nathan DM, et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes, 2003, 52: 2160-2167.
9Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab, 2000, 26: 98-106.
10Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med, 1999, 107: 450-455.
